学术会议:紧随研究趋势 洞察学术热点 进入>
产业会议:新技术,新领域,深入产业环节 进入>
举办会议及论坛超过百场 邀请海内外院士超过50名 教授PI专家授课超过1000名 总参会人数超过10万人
2017-11-02至2017-11-03 中国上海
Menu
报名参会
Sign up

大会主席CongressChairman

丁健 院士

中科院上海药物研究所

丁健 院士

中科院上海药物研究所

个人简介:

丁健,日本九州大学医学博士、肿瘤药理学家、中国工程院院士、发展中国家科学院院士。现任中国科学院大学药学院院长、中国科学院学术委员会生命与健康专门委员会委员、中科院上海药物所学术委员会主任、上海市浦东新区科协主席、上海市浦东新区生物产业行业协会会长。担任Acta Pharmacol. Sin.(中国药理学报)主编和Eur J Pharmacol、J Ethnopharmacol 和Molecular Pharmacology等SCI学术杂志编委。在抗肿瘤新药研发创制方面,作为主要发明者之一研发的具有自主知识产权的8个候选新药在国内外处于临床I-III期临床研究,2个新药正在申报临床,另外有一批候选药物正在进行系统临床前研究。申请国内外专利180余项,其中获国内外专利授权70余项。在药物作用机制探索和生物标志物研究方面,系统阐明了一系列抗肿瘤化合物或候选新药的作用机制;阐明了数个药靶相互作用的结构基础与作用模式,发现了pIgR、CXCL12、p27/KIP1、c-Myc等重要肿瘤生物标志物。在Cancer Cell、J Nat Cancer Inst、Nature Com、Cell Res、Hepatology、Clin Cancer Res、Cancer Res、J Cell Biology等发表SCI论文270多篇,他引5700余次。获国家自然科学奖二等奖、国家科技进步二等奖、上海市自然科学一等奖、何梁何利科技进步奖、谈家桢生命科学成就奖、中科院杰出科技成就奖等奖项10余项。

代表论著:

1. Ai J, Tang QJ, Wu YL, Xu Y, Feng T, Zhou RY, Chen Y, Gao X, Zhu QF, Yue XH, Pan QN, Xu SY, Li J, Huang M, Daugherty-Holtrop J, He YZ, Xu HE, Fan J*, Ding J*, Geng M*. The Role of Polymeric Immunoglobulin Receptor in Inflammation-Induced Tumor Metastasis of Human Hepatocellular Carcinoma. J Natl Cancer Inst. 103:1696-712, 2011

 

2. Jiang Y., Miao ZH*., Xu L., Yu B., Gong JX., Tong LJ., Chen Y., Zhou ZL., Liu HC., Wang Y., Guo YW., Ding J*. Drug transporter-independentliver cancer cell killing by marine steroid methyl spongoate via intrinsic and extrinsic apoptosis pathways. J BiolChem 286:26461-9, 2011

 

3. Zhang J, Xin X, Chen Q, Xie Z, Gui M, Chen Y, Lin L, Feng J, Li Q, Ding J*, Geng M*. Oligomannurarate sulfate sensitizes cancer cells to doxorubicin by inhibiting atypical activation of NF-κB via targeting of Mre11. Int J Cancer. 130: 467–477, 2012

 

4. Chen G, Chen SM, Wang X, Ding XF, Ding J*, Meng LH*. Inhibition of Chemokine (CXC Motif) Ligand 12/Chemokine (CXC Motif) Receptor 4 Axis CXCL12/CXCR4)-mediated Cell Migration by Targeting Mammalian Target of Rapamycin (mTOR) Pathway in Human Gastric Carcinoma Cells. J Biol Chem. 287(15):12132-41, 2012 .

 

5. Chen SM, Liu JL, Wang X, Liang C, Ding J*, Meng LH*. Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR. BiochemPharmacol. 83(9):1183-94, 2012.

 

6. Yu B, Li MH, Wang W, Wang YQ, Jiang Y, Yang SP, Yue JM, Ding J*, Miao ZH*. Pseudolaric acid B-driven phosphorylation of c-Jun impairs its role in stabilizing HIF-1alpha: a novel function-converter model. J Mol Med (Berl). 90(8):971-81,2012.

 

7. Zhou Y, Chen Y, Tong L, Xie H, Wen W, Zhang J, Xi Y, Shen Y, Geng M, Wang Y, Jiang H, Luo C, Lin L*, Ding J*. AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and antitumor activity via targeting VEGFR, FGFR, and PDGFR. J Cell Mol Med. 16(10):2321-2330, 2012.

 

8. Zhu CH., Chen Q., XieZQ., Ai J., Tong LJ., Ding J*., Geng MY*. The role of histone deacetylase 7 (HDAC 7) in cancer cell proliferation: regulation on c-Myc. J Mol Med 89: 279-89, 2011

 

9. Zhang ZX., Meng T., Yang N., Wang W., Xiong B., Chen Y., Ma LP., Shen JK., Miao ZH*, Ding J*. MT119, a new planar-structured compound, targets the colchicine site of tubulin arresting mitosis and inhibiting tumor cell proliferation. Inter J Cancer 129: 214-24, 2011.

 

10. Chen G, Yang N, Wang X, Zheng SY, Chen Y, Tong LJ, LI YX, Meng L*., Ding J*.Identification of p27/KIP1 expression level as a candidate biomarker of response to rapalogs therapy in human cancer. J Mol Med 88: 941-52, 2010

 

11. Li M, Miao ZH, Chen Z, Chen Q, Gui M, Lin LP, Sun P, Yi YH, Ding J*. Echinoside A, a new marine-derived anticancer saponin, targets topoisomerase II? by unique interference with its DNA binding and catalytic cycle. Ann Oncol 21: 597-607, 2010.

 

12. Li T, Wang J, Wang X, Yang N, Chen SM, Tong LJ, Yang CH, Meng LH, Ding J*. WJD008, a dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin inhibitor, prevents PI3K signaling and inhibits the proliferation of transformed cells with oncogenic PI3K mutant. J PharmacolExpTher. 334:830-8, 2010

 

13. Lu JJ.,Meng LH*., Shankavaramb UT., Zhu CH., Tong LJ., Chen G., Lin LP., Weinsteinc JN., Ding J*. Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells. BiochemPharmacol 80: 22-30, 2010.

 

14. Yu B, Miao ZH, Jiang Y, Li MH, Yang N, Li T, Ding J*. c-Jun Protects Hypoxia-Inducible Factor-1{alpha} from Degradation via Its Oxygen-Dependent Degradation Domain in a Nontranscriptional Manner. Cancer Res. 69:7704-12, 2009

 

15. Li Z, Zhou ZL, Miao ZH, Lin LP, Feng HJ, Tong LJ, Ding J*, Li YC*. Design and synthesis of novel C14-hydroxyl substituted triptolide derivatives as potential selective antitumor agents. J Med Chem. 52:5115-23, 2009

 

16. Zhu H, Miao ZH*, Huang M, Feng JM, Zhang ZX, Lu JJ, Cai YJ, Tong LJ, Xu YF, Qian XH, Ding J*. Naphthalimides induce G2 phase arrest in HCT-116 cells via ATM-activated Chk2-executed pathway. Neoplasia 11: 1226–34. 2009

 

17. Zhang C, Yang N, Yang CH, Ding HS, Luo C, Zhang Y, Wu MJ, Zhang XW, Shen X, Jiang HL, Meng LH, Ding J*. S9, a novel anticancer agent, exerts its anti-proliferative activity by interfering with both PI3K-Akt-mTOR signaling and microtubule cytoskeleton. PLoS One. 2009;4(3):e4881.

 

18. Ren X, Dai M, Lin LP, Li PK, Ding J*. Anti-angiogenic and vascular disrupting effects of C9, a new microtubule-depolymerizing agent. Br J Pharmacol. 156 :1228-38, 2009.


邀请函

下载邀请函

赞助企业

报名参会
大会咨询
姓名 *

E-mail*

电话: *

消息: *

×
留下姓名电话和邮箱,邀请函直接发送到邮箱
*姓名:
* 电话:
* Email: